[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574288":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":23,"centralContacts":27,"locations":23,"responsibleParty":33,"collaborators":23,"id":35,"slug":36,"hasResults":37,"nctId":38,"briefTitle":39,"officialTitle":40,"acronym":23,"eligibilityCriteria":41,"healthyVolunteers":37,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":23,"studyType":48,"phases":49,"briefSummary":52,"conditions":53,"keywords":23,"overallStatus":55,"whyStopped":23,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":23},{"fullName":5,"class":6},"Hinova Pharmaceuticals Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HP568","EXPERIMENTAL","In the I\u002FII stage: HP568 administered QD or BID for 28 day cycles.",[13],"Drug: HP568",{"label":15,"type":10,"description":16,"interventionNames":17},"HP568 and palbociclib","In the III stage: Daily oral dosages of HP568 for 28 days in combination with palbociclib for 21 days.",[18],"Drug: HP568 in combination with palbociclib",[20,24],{"type":21,"name":9,"description":11,"armGroupLabels":22,"otherNames":23},"DRUG",[9],null,{"type":21,"name":25,"description":16,"armGroupLabels":26,"otherNames":23},"HP568 in combination with palbociclib",[15],[28],{"name":29,"role":30,"phone":31,"phoneExt":23,"email":32},"Zhonghua Zhou","CONTACT","+86-28-85058465","zhzhou1@hinovapharma.com",{"type":34,"investigatorFullName":23,"investigatorTitle":23,"investigatorAffiliation":23,"oldNameTitle":23,"oldOrganization":23},"SPONSOR","100574288","phase-1-a-phase-iii-trial-to-evaluate-oral-hp568-tablets-in-patients-with-erher2-advanced-breast-cancer-100574288",false,"NCT06757335","A Phase I\u002FII Trial to Evaluate Oral HP568 Tablets in Patients with ER+\u002FHER2 Advanced Breast Cancer","A Multicenter, Open, Dose Escalation\u002Fdose Escalation, and Phase I\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral HP568 Tablets Alone and in Combination with Palbociclib in Patients with ER+\u002FHER2 Advanced Breast Cancer","Inclusion Criteria:\n\n1. Women aged 18-75 years old (inclusive of both ends) at the time of signing the informed consent form.\n2. Patients with locally advanced inoperable or recurrent or metastatic breast cancer ER+\u002FHER2- advanced breast cancer is confirmed by histopathology have confirmed that the primary and\u002For metastatic lesion.\n3. Previously received at least 1-line endocrine therapy (endocrine therapy duration ≥ 6 months) and ≤ 2-line chemotherapy (≤ 2-line chemotherapy limited to dose escalation stage) for the recurrence or metastasis stage of the disease. The third stage : Inclusion of patients who have not received prior treatment but are suitable for CDK4\u002F6i therapy.\n4. Disease progression confirmed by imaging occurs during or after the last systemic anti-tumor treatment before the first medication.\n\nExclusion Criteria:\n\n1. Known or suspected allergy to any ingredient of HP568 formulation, and allergy to any ingredient of palbociclib (only applicable to stage III).\n2. Within 42 days prior to the first administration, Fluvistran was used; Other endocrine therapies such as tamoxifen, toremifene, letrozole, anastrozole, and exemestane were used within 14 days prior to the first administration.\n3. Previously received other ER-ROTAC drugs such as ARV-471.\n4. Within 6 weeks before the first administration of HP568 in this study, nitrosoureas or mitomycin were used; Received any anti-tumor treatment, including immunotherapy, chemotherapy, radiotherapy, or targeted therapy, within 28 days prior to the first administration (or of the drug's 5 half lives,take the shorter one).","FEMALE","18 Years","75 Years",{"count":46,"type":47},204,"ESTIMATED","INTERVENTIONAL",[50,51],"PHASE1","PHASE2","This is a Phase 1\u002F2 dose escalation and cohort expansion study and will assess the safety, tolerability and preliminary efficacy of HP568 alone and in combination with palbociclib in patients with ER+\u002FHER2- locally advanced or metastatic breast cancer.",[54],"Breast Cancer","NOT_YET_RECRUITING","2025-01-01",{"date":58,"type":59},"2025-01-03","ACTUAL",{"date":61,"type":47},"2025-01-07",{"date":63,"type":47},"2026-11-27",{"name":5,"class":6}]